{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:15:04Z","timestamp":1783196104264,"version":"3.54.6"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,29]],"date-time":"2027-04-29T00:00:00Z","timestamp":1808956800000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["75R60222C00011"],"award-info":[{"award-number":["75R60222C00011"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100026309","name":"National Marrow Donor Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026309","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.coi.2026.102783","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:15:43Z","timestamp":1777569343000},"page":"102783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy"],"prefix":"10.1016","volume":"100","author":[{"given":"Brian C","family":"Shaffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen E","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102783_bib1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102783_bib2","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102783_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(12)70004-9","article-title":"Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study","volume":"13","author":"Fleischhauer","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coi.2026.102783_bib4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2020008464","article-title":"Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM","volume":"137","author":"Meurer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102783_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2017-07-798751","article-title":"Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion","volume":"131","author":"Oran","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102783_bib6","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","article-title":"Impact of immune modulation with anti\u2013T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies","volume":"117","author":"Soiffer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102783_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2015.09.012","article-title":"On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source","volume":"22","author":"Besse","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2026.102783_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2026.102783_bib9","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102783_bib10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102783_bib11","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2026.102783_sbref12","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO-25-00856","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation","volume":"43","author":"Al Malki","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2026.102783_bib13","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide\u2013based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","volume":"42","author":"Shaffer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2026.102783_bib14","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102783_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy \u2014 a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.coi.2026.102783_bib16","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/bloodadvances.2024014858","article-title":"Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis","volume":"9","author":"Nath","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102783_bib17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jtct.2025.11.010","article-title":"Access to allogeneic cell transplantation based on donor search prognosis: BMT CTN 1702 trial","volume":"32","author":"Dehn","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.coi.2026.102783_sbref18","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO-25-00206","article-title":"Primary results from blood and marrow transplant clinical trials network 1702: clinical transplant-related long-term outcomes of alternative donor allogeneic transplantation","volume":"43","author":"Lee","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2026.102783_bib19","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/ajh.27084","article-title":"Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia","volume":"98","author":"Nath","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coi.2026.102783_bib20","doi-asserted-by":"crossref","first-page":"345.e1","DOI":"10.1016\/j.jtct.2025.10.001","article-title":"Search summary score: a global measure to predict matched unrelated stem cell donor availability","volume":"32","author":"Fingerson","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.coi.2026.102783_bib21","first-page":"973","article-title":"Allogeneic hematopoietic cell donor selection: contemporary guidelines from the NMDP\/CIBMTR","volume":"31","author":"Jimenez Jimenez","year":"2025","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.coi.2026.102783_bib22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy","volume":"127","author":"Kollman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102783_bib23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2018.02.006","article-title":"Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most","volume":"24","author":"Shaw","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2026.102783_bib24","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102783_bib25","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1182\/bloodadvances.2024013756","article-title":"Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes","volume":"8","author":"Spellman","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102783_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/bloodadvances.2025017194","article-title":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using post-transplant cyclophosphamide","volume":"10","author":"Modi","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102783_bib27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102783_bib28","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102783_bib29","first-page":"258","article-title":"Targeting Menin disrupts the KMT2A\/B and polycomb balance to paradoxically activate bivalent genes","volume":"25","author":"Sparbier","year":"2023","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.coi.2026.102783_bib30","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/2159-8290.CD-21-0980","article-title":"Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse","volume":"12","author":"Gambacorta","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coi.2026.102783_bib31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41698-024-00665-z","article-title":"Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities","volume":"8","author":"Lozac\u2019hmeur","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.coi.2026.102783_bib32","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102783_bib33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/blood-2015-12-686238","article-title":"Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT","volume":"128","author":"Crivello","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102783_bib34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12185-023-03621-y","article-title":"Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation","volume":"118","author":"Barakat","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.coi.2026.102783_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbmt.2012.07.020","article-title":"Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease","volume":"19","author":"Rutten","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2026.102783_bib36","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.2024024105","article-title":"HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","volume":"144","author":"Krakow","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.coi.2026.102783_bib37","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/blood-2023-187355","article-title":"Initial results of a phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to prevent relapse after allogeneic hematopoietic cell transplantation","volume":"142","author":"Al Malki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102783_sbref38","article-title":"Do 2 year patient outcomes differ by donor type using contemporary graft vs host disease prophylaxis post-transplant? A CIBMTR retrospective analysis","author":"Devine","year":"2025","journal-title":"EBMT Annu Meet Abstr"},{"key":"10.1016\/j.coi.2026.102783_bib39","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:17:05Z","timestamp":1783192625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"alternative-id":["S0952791526000609"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102783","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102783"}}